Our latest articles
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.